cancer inhibitors trang 12 tải miễn phí từ TAILIEUCHUNG

"cancer inhibitors" trang 12 - tải miễn phí từ Tailieuchung

Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment

Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment

11 25 1

Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: A case report

Prolonged survival of a patient with metastatic leptomeningeal melanoma treated with BRAF inhibition-based therapy: A case report

5 30 1

The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ

The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ

7 36 1

Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin

Treatment of medulloblastoma with oncolytic measles viruses expressing the angiogenesis inhibitors endostatin and angiostatin

13 22 1

Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS

Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS

15 35 1

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments

13 58 1

The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells

The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells

11 23 1

Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models

Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models

9 31 1

TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages

TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages

10 57 1

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism

Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism

10 42 1

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGF RA D842V mutation: A retrospective analysis of clinical trial and real-world data

Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGF RA D842V mutation: A retrospective analysis of clinical trial and real-world data

9 21 1

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

8 20 1

Hospitalization at the end of life in patients with multiple myeloma

Hospitalization at the end of life in patients with multiple myeloma

6 22 1

Efficacy and safety of apatinib in the treatment of osteosarcoma: A single-arm meta-analysis among Chinese patients

Efficacy and safety of apatinib in the treatment of osteosarcoma: A single-arm meta-analysis among Chinese patients

11 38 1

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma

Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma

13 13 1

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

14 47 1

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy

12 43 1

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

9 42 1

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival

10 28 1

PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis

PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis

10 19 1

Đầu
1
2
3
4
5
6
7
8
9
10
11
[ 12 ]
13
14
Cuối

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.